RNA oxidation adducts 8-OHG and 8-OHA change with Aβ 42 levels in late-stage Alzheimer's disease

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Weidner, Adam M ^a   Bradley, Melissa A ^a   Beckett, Tina L ^a   Niedowicz, Dana M ^a   Dowling, Amy L S ^a,b   Matveev, Sergey V ^a   LeVine III, Harry ^a   Lovell, Mark A ^a,b   Murphy, M Paul ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYADENINE; 8 HYDROXYGUANINE; ADENINE DERIVATIVE; AMYLOID BETA PROTEIN[1-42]; DODECYL SULFATE SODIUM; FORMIC ACID; RNA; UNCLASSIFIED DRUG; 8-HYDROXYADENINE; 8-HYDROXYGUANINE; ADENINE; AMYLOID BETA PROTEIN; DRUG DERIVATIVE; GUANINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; INFERIOR PARIETAL LOBULE; MALE; MASS SPECTROMETRY; MIDDLE TEMPORAL GYRUS; MULTIPLE REGRESSION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; OXIDATION; PATHOGENESIS; PREDICTION; RNA OXIDATION; SENILE PLAQUE; STRIATE CORTEX; SUPERIOR TEMPORAL GYRUS; AMYLOID PLAQUE; BRAIN; CASE CONTROL STUDY; CHEMISTRY; COMPARATIVE STUDY; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; MASS FRAGMENTOGRAPHY; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

ADENINE; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; CASE-CONTROL STUDIES; DNA DAMAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GUANINE; HUMANS; MALE; NEUROFIBRILLARY TANGLES; OXIDATION-REDUCTION; PLAQUE, AMYLOID; RNA;

EID: 80052934408     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024930     Document Type: Article

References (42)

1. Kochanek KD, Xu J, Murphy SL, Minino AM, Kung H-C, (2011) Deaths: Preliminary Data for 2009. National Vital Statistics Reports 59: 1-6.
2. Butterfield DA, Drake J, Pocernich C, Castegna A, (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7: 548-554.
3. Hardy JA, Higgins GA, (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185.
4. Duering M, Grimm MO, Grimm HS, Schroder J, Hartmann T, (2005) Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiol Aging 26: 785-788.
5. Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, et al. (2008) Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. Arch Neurol 65: 906-912.
6. Ermak G, Davies KJ, (2003) DSCR1(Adapt78)-a Janus gene providing stress protection but causing Alzheimer's disease? IUBMB Life 55: 29-31.
7. Duyckaerts C, Delatour B, Potier MC, (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol 118: 5-36.
8. Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, et al. (2010) Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol 20: 66-79.
9. Moreira PI, Nunomura A, Nakamura M, Takeda A, Shenk JC, et al. (2008) Nucleic acid oxidation in Alzheimer disease. Free Radic Biol Med 44: 1493-1505.
10. Butterfield DA, Lauderback CM, (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32: 1050-1060.
11. Cheng KC, Cahill DS, Kasai H, Nishimura S, Loeb LA, (1992) 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions. J Biol Chem 267: 166-172.
12. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, et al. (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 19: 1959-1964.
13. Ding Q, Markesbery WR, Cecarini V, Keller JN, (2006) Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem Res 31: 705-710.
14. Hu J, de Souza-Pinto NC, Haraguchi K, Hogue BA, Jaruga P, et al. (2005) Repair of formamidopyrimidines in DNA involves different glycosylases: role of the OGG1, NTH1, and NEIL1 enzymes. J Biol Chem 280: 40544-40551.
15. Lovell MA, Gabbita SP, Markesbery WR, (1999) Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 72: 771-776.
16. Guentchev M, Siedlak SL, Jarius C, Tagliavini F, Castellani RJ, et al. (2002) Oxidative damage to nucleic acids in human prion disease. Neurobiol Dis 9: 275-281.
17. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, et al. (1999) Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154: 1423-1429.
18. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, et al. (2000) "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology 55: 370-376.
19. Nelson PT, Abner EL, Scheff SW, Schmitt FA, Kryscio RJ, et al. (2009) Alzheimer's-type neuropathology in the precuneus is not increased relative to other areas of neocortex across a range of cognitive impairment. Neurosci Lett 450: 336-339.
20. Murphy MP, Beckett TL, Ding Q, Patel E, Markesbery WR, et al. (2007) Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis 27: 301-311.
21. Beckett TL, Niedowicz DM, Studzinski CM, Weidner AM, Webb RL, et al. (2010) Effects of nonsteroidal anti-inflammatory drugs on amyloid-beta pathology in mouse skeletal muscle. Neurobiol Dis 39: 449-456.
22. LeVine H 3rd, (2004) Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem 335: 81-90.
23. Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, et al. (2003) Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 23: 8532-8538.
24. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, et al. (2006) Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 116: 193-201.
25. Rosen RF, Ciliax BJ, Wingo TS, Gearing M, Dooyema J, et al. (2010) Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol 119: 221-233.
26. Rosen RF, Walker LC, Levine H 3rd, (2011) PIB binding in aged primate brain: enrichment of high-affinity sites in humans with Alzheimer's disease. Neurobiol Aging 32: 223-234.
27. Rio DC, Ares M Jr, Hannon GJ, Nilsen TW, (2010) Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc 2010 pdb prot5439.
28. Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA, (2005) Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem 93: 953-962.
29. Holm S, (1979) A Simple Sequentially Rejective Multiple Test Procedure. Scandinavian Journal of Statistics 6: 65-70.
30. Bhattacharya PK, Barton JK, (2001) Influence of intervening mismatches on long-range guanine oxidation in DNA duplexes. J Am Chem Soc 123: 8649-8656.
31. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60: 759-767.
32. Prat F, Houk KN, Foote CS, (1998) Effect of guanine stacking on the oxidation of 8-oxoguanine in B-DNA. J Am Chem Soc 120: 845-846.
33. Upadhaya AR, Lungrin I, Yamaguchi H, Fandrich M, Thal DR, (2011) High-molecular weight Abeta-oligomers and protofibrils are the predominant Abeta-species in the native soluble protein fraction of the AD brain. J Cell Mol Med Epub ahead of print.
34. Ferreira ST, Vieira MN, De Felice FG, (2007) Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59: 332-345.
35. Stefani M, Dobson CM, (2003) Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81: 678-699.
36. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, et al. (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain 133: 1328-1341.
37. Murphy MP, LeVine H 3rd, (2010) Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 19: 311-323.
38. Braak H, Braak E, (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259.
39. Lovell MA, Markesbery WR, (2007) Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 35: 7497-7504.
40. Lovell MA, Markesbery WR, (2008) Oxidatively modified RNA in mild cognitive impairment. Neurobiol Dis 29: 169-175.
41. Miners JS, van Helmond Z, Kehoe PG, Love S, (2010) Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol 20: 794-802.
42. Miners JS, Morris S, Love S, Kehoe PG, (2011) Accumulation of insoluble amyloid-beta in down's syndrome is associated with increased BACE-1 and neprilysin activities. J Alzheimers Dis 23: 101-108.